How many drugs treat Renal osteodystrophy?

Drug Landscape tracks 3 marketed treatments for Renal osteodystrophy (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/renal-osteodystrophy.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Renal osteodystrophy — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Renal osteodystrophy (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Renal osteodystrophy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Calcijex	CALCITRIOL	Esjay Pharma	Vitamin D3 Analog [EPC]	Vitamin D3 receptor	1978-01-01
Rocaltrol	Rocaltrol	Shandong University		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein
Alphacalcidol	Alphacalcidol	University of Ioannina		Sodium-dependent noradrenaline transporter, Vitamin D3 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Renal osteodystrophy
Esjay Pharma · 1 drug in Renal osteodystrophy
Shandong University · 1 drug in Renal osteodystrophy
University of Ioannina · 1 drug in Renal osteodystrophy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Renal osteodystrophy:

Cite this brief

Drug Landscape (2026). Renal osteodystrophy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/renal-osteodystrophy. Accessed 2026-06-10.

Renal osteodystrophy full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing